Sol Gel Technologies Stock Today
| SLGL Stock | USD 0.98 0.67 40.61% |
Performance6 of 100
| Odds Of DistressLess than 24
|
Sol Gel is selling for 0.98000002 as of the 25th of December 2024. This is a 40.61 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.41. Sol Gel has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of November 2024 and ending today, the 25th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of January 2018 | Category Healthcare | Classification Health Care |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. Sol-Gel Technologies Ltd. The company has 27.86 M outstanding shares of which 50.46 K shares are at this time shorted by private and institutional investors with about 0.59 trading days to cover. More on Sol Gel Technologies
Moving against Sol Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Sol Stock Highlights
| CEO, Co-Founder, Director | Alon SeriLevy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Karachi All Share, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSol Gel can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sol Gel's financial leverage. It provides some insight into what part of Sol Gel's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sol Gel Technologies (SLGL) is traded on NASDAQ Exchange in USA. It is located in 7 Golda Meir Street, Ness Ziona, Israel, 7403650 and employs 36 people. Sol Gel is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.97 M. Sol Gel Technologies conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 27.86 M outstanding shares of which 50.46 K shares are at this time shorted by private and institutional investors with about 0.59 trading days to cover.
Sol Gel Technologies currently holds about 36.61 M in cash with (17.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sol Gel Probability Of Bankruptcy
Ownership AllocationSol Gel Technologies shows a total of 27.86 Million outstanding shares. Sol Gel Technologies has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.16 % of Sol Gel outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sol Ownership Details
Sol Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Securities, Llc | 2024-09-30 | 25.9 K | |
| Geode Capital Management, Llc | 2024-09-30 | 13.4 K | |
| Xtx Topco Ltd | 2024-09-30 | 10.9 K | |
| Cetera Investment Advisers | 2024-09-30 | 10.5 K | |
| Steward Partners Investment Advisory, Llc | 2024-09-30 | 4.2 K | |
| Ubs Group Ag | 2024-09-30 | 3.5 K | |
| Blackrock Inc | 2024-06-30 | 3.1 K | |
| Bank Of America Corp | 2024-09-30 | 2.4 K | |
| Simplex Trading, Llc | 2024-06-30 | 726 | |
| Phoenix Financial Ltd | 2024-09-30 | 2.5 M | |
| Migdal Insurance & Financial Holdings Ltd | 2024-06-30 | 1.2 M |
Sol Gel Historical Income Statement
Sol Stock Against Markets
Sol Gel Corporate Management
| Tamar Jutkowitz | VP Counsel | Profile | |
| Gilad Mamlok | Chief Officer | Profile | |
| Pr Avnir | CoFounder | Profile | |
| Moshe Arkin | Executive Board | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sol Gel Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sol Gel. If investors know Sol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sol Gel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 0.235 | Quarterly Revenue Growth 8.146 | Return On Assets (0.22) | Return On Equity (0.36) |
The market value of Sol Gel Technologies is measured differently than its book value, which is the value of Sol that is recorded on the company's balance sheet. Investors also form their own opinion of Sol Gel's value that differs from its market value or its book value, called intrinsic value, which is Sol Gel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sol Gel's market value can be influenced by many factors that don't directly affect Sol Gel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sol Gel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sol Gel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sol Gel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.